Document:

Summary of Terms of Employment

 Exhibit 10.28 
  

			
	

	 	Hexion Specialty Chemicals, Inc.
	 	  
 180 East Broad Street

	 	Columbus, OH 43215
	 	hexionchem.com

 August 3, 2009 
 Julia Harp 
 Louisville, KY 
 Dear Julia: 
 It is a pleasure to confirm your
promotion to the role of EVP and President, Coatings and Inks Division. The purpose of this letter is to outline the compensation terms of your transition to this role. In your new position you will be located in Columbus, Ohio and report to me.

 Please acknowledge acceptance of this offer by signing in the space provided on the second page and returning the original letter in the
envelope provided. This letter contains the terms and conditions of this offer, no others are authorized and you acknowledge that you are not relying on any such terms or conditions. 
 If you have any questions or there is anything requiring clarification, please give me a call. 
 Sincerely, 
 /s/ Craig O. Morrison 
 Craig O. Morrison 
 President and Chief Executive Officer 
 Hexion Specialty Chemicals, Inc. 
  

	cc:	Judy Sonnett 

 HEXION SPECIALTY CHEMICALS, INC. 
 SUMMARY OF TERMS OF EMPLOYMENT 
 FOR JULIA HARP 
  

			
	Position:	  	EVP and President, Coatings and Inks Division
		
	Base Salary:	  	$300,000 per year, paid bi-weekly. You will be paid out of the United States in USD on a bi-weekly basis, with your checks being electronically deposited to your bank checking or
savings account(s).
		
	Effective Date:	  	August 3, 2009
		
	Sign on Bonus:	  	$10,000 payable within 30 days of the date of your promotion.
		
	Company Car:	  	You are asked to relinquish your company car by October 2, 2009, as company cars are not authorized for Senior Leaders based in the U.S.
		
	Incentive:	  	You will continue to be eligible to participate in the Hexion Incentive Compensation Plan. Your new target incentive award increases to 70% of your new base salary. The Incentive
Compensation Plan is contingent upon the achievement of specific company economic goals. The terms of this plan and eligibility for participation are reviewed annually and approved by the Compensation Committee of the Board of
Directors.
		
		  	You will also be eligible for an additional discretionary award which will reflect the contributions you made to both the Global Phenolics business and the Global Coatings and
Inks Division performance for 2009.
		
	Long Term Incentive	  	The Board of Directors has agreed to modify the 2009 LTI you were recently awarded. You originally were offered 100% of your base salary, and that is now being increased to a
total of 200% of your base salary. The plan design features remain consistent.
		
	Benefits:	  	You continue in the same benefit plans that you participate in today. Your vacation benefits will now increase to 4 weeks annually, with your promotion.
		
	Relocation:	  	You will be based in your new headquarters location no later than September 2010. Between August 2009 and September 2010, temporary living expenses will be paid by the Company.
We will assist you in making these arrangements to ensure a safe, comfortable and economic solution. You are offered to relocate under the Hexion Homeowner Buyout relocation policy or to accept a $100,000 cash payout in lieu of selling your home.
The cash payout would be used toward renting or buying locally if you prefer not to sell your current home. Before initiating any action with your move, please contact Nancy Leonard at SIRVA Relocation; phone 630-570-8968. She has been retained by
Hexion to assist you with all phases of your move and can help you with any questions you may have.
		
	Terms of Plans:	  	Some of the above are highlights of various plans or programs, and all are subject to the terms of the actual plans and programs.

			
	“AT WILL” Statement:	  	The legal nature of this employment contract is one “AT WILL”, which means that either you or the Company can end this relationship at any time.
		
	Severance:	  	If you were to lose your job through no fault of your own, you will be eligible to receive 12 months severance.

  

							
	OFFER ACCEPTED:	 		  		  	
				
	 /s/ Julia D. Harp
	 		  	 8/24/09
	  	
	Julia Harp	 		  	DateSummary of Terms of Employment

 Exhibit 10.29 
  

			
	

	 	Hexion Specialty Chemicals, Inc.
	 	  
 180 East Broad Street

	 	Columbus, OH 43215
	 	hexionchem.com

 September 21, 2007 
 Ms. Judith Sonnett 
 Dear Judy, 

To further our conversation, I am pleased to extend our promotional offer to the position of Executive Vice President, Human Resources for Hexion
Specialty Chemicals, Inc. 
 Attached is a summary of the terms of the offer. The position is located at our Columbus, Ohio headquarters and
will report directly to me. The effective date of your new position will be September 10, 2007. 
 Please acknowledge acceptance of this
offer by signing in the space provided on the second page and returning it to me in the envelope provided. This offer letter contains all of the terms and conditions of your employment, no others are authorized and you acknowledge that you are not
relying on any other terms or conditions. 
 Judy, I look forward to your once again becoming a member of the Hexion Specialty Chemicals, Inc.,
Senior Leadership Team and believe you will continue to play a key role in building value toward our future success. If you have any immediate questions, please give me a call. 
 Sincerely, 
 /s/ Craig O. Morrison 
 Craig O. Morrison 
 President and Chief Executive Officer 
 Hexion Specialty Chemicals, Inc. 

 HEXION SPECIALTY CHEMICALS, INC. 
 SUMMARY OF TERMS OF EMPLOYMENT 
 FOR: Judith Sonnett 
  

			
	Position:	  	Executive Vice President, Human Resources
		
	Effective Date:	  	September 10, 2007
		
	Base Salary:	  	$ 340,000 per year
		
	Annual Incentive:	  	Based on your new position and salary, you will continue to be eligible to participate in the 2007 Hexion Incentive Plan with a new incentive award target of 60% of your annual
base salary effective September 1. The maximum payout of the plan is 200% of your target award. The incentive is based on the company achieving our financial objectives as well as team and individual incentive goals. Based on the plan requirements,
the calculation for ICP will be prorated as follows: the first 8 months of the year will be calculated based on your pay and ICP target prior to assuming your new position and the remaining 4 months will be calculated based on your new rate of pay
and ICP target.
		
	Long Term Incentive:	  	You will be nominated in October 2007 for an award in the new Hexion Long Term Incentive Plan. Your award allows you to participate in the value creation of Hexion Specialty
Chemicals, Inc. You will be nominated for an award of 3,000 Restricted Stock Units (RSUs) and 9,000 stock options, which is commensurate with other Executive Vice Presidents at your level within the organization. Gayle Brocksmith, Vice President of
Global Compensation is your primary resource for explaining the Long Term Incentive Plan in greater detail.
		
	Benefits:	  	Your participation in the Hexion benefit programs will remain unchanged.
		
	Company Agreements:	  	Enclosed is a Non-Disclosure, Fair Competition, and Inventions Agreement that is required to be read, understood and signed by you. Compliance with The Hexion Specialty
Chemicals, Inc. Code of Business Ethics and the Antitrust Compliance Manual is a condition of employment.
		
	Terms of Plans:	  	Some of the above are highlights of various plans or programs, and all are subject to the terms of the actual plans and programs.

			
	“AT WILL” Statement:	  	This offer of employment is for an “AT WILL” position, which means that either you or the Company can end this relationship at any time.

  

							
	OFFER ACCEPTED:	 		  		  	
				
	 /s/ Judith A. Sonnett
	 		  	 10/17/07
	  	
	Judith Sonnett	 		  	DateAmended and Restated Development

 Exhibit 10.25 
 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS 
 AMENDED AND RESTATED DEVELOPMENT, MANUFACTURING, LICENSING 
 AND SUPPLY AGREEMENT 
 THIS AMENDED AND RESTATED DEVELOPMENT, MANUFACTURING, LICENSING AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of February 19, 2010 (the “Effective Date”) by and between DEXCOM, INC.,
a Delaware corporation, having an address of 6340 Sequence Drive, San Diego, California 92121 (“Purchaser”), and, DSM PTG, INC., a California corporation, with its principal office at 2810 Seventh St., Berkeley, CA 94710
(“Supplier”). 
 RECITALS 
 WHEREAS, Purchaser is in the business of developing, manufacturing, marketing and selling continuous glucose monitoring products.

 WHEREAS, Supplier is in the business of developing, manufacturing and packaging specialty polymers and biomedical
materials including polymeric materials; and 
 WHEREAS, Purchaser desires to utilize Supplier as a contract developer
and manufacturer to develop Development Materials (defined below), and to manufacture, package, store and ship Commercial Materials (as defined below) and Current Materials (as defined below) in accordance with the terms and conditions set forth
herein; and 
 WHEREAS, Purchaser desires to obtain an exclusive license to the Commercial Materials and under the
Subject Technology in the Field; and 
 WHEREAS, Supplier is willing to grant an exclusive license for a defined period
of time and a non exclusive license for the period thereafter to the Commercial Material set forth on Exhibit C-2 ([*****]) and under the Subject Technology in the Field to Purchaser subject to the terms set forth herein; 
 WHEREAS, Supplier is willing to grant an exclusive license to Development Materials (including Development Materials that become
Commercial Materials as set forth herein) and under the Subject Technology in the Field to Purchaser subject to the terms set forth herein; 
 WHEREAS, this Agreement shall supersede the Manufacturing and Supply Agreement between Purchaser and Supplier, dated April 3, 2008. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1.
DEFINED TERMS. 
 1.1 “Acceptance Period” shall have the meaning provided in
Section 7.3(b). 
 DexCom Confidential 

 1.2 “Adverse Event” shall mean any adverse event associated
with the use of any Commercial Materials or Current Materials, including an adverse event occurring in the course of the use of Commercial Materials or Current Materials in commercial practice, in studies, in investigations or in tests. 

1.3 “Affiliate” shall mean, with respect to any party hereto, any entity that controls, is controlled by,
or is under common control with such party. For the purposes of this definition, a party shall be deemed to control another entity if it owns or controls, directly or indirectly, more than fifty percent (50%) of the voting equity of the other
entity (or other comparable ownership interest for an entity other than a corporation) and if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such other entity. 
 1.4 “Applicable Laws” shall mean all United States federal, state and local laws, statutes, rules,
regulations, ordinances (including any amendments thereto), applicable to the import, export, manufacture and distribution of the Commercial Materials and Current Materials. In the event of any conflict between the foregoing sources of authority,
U.S. federal law and regulations shall be given priority. 
 1.5 “Approval Application” shall
mean an application for Regulatory Approval required before commercial sale or use of the Commercial Materials in combination with any of Purchaser’s Products in any applicable regulatory jurisdiction. 
 1.6 “Certificate of Analysis” shall have the meaning provided in Section 4.4. 
 1.7 “Commercial Material(s)” shall mean (i) Supplier’s proprietary [*****], which meets the
applicable Materials Specifications set forth at Exhibit C-2 and as is defined in Exhibit C-2, as well as (ii) Development Materials that, upon completion of development pursuant to an applicable Statement of Work, and which
receives final written approval from Purchaser that such material meets both the Materials Specifications and Purchaser’s Quality Systems, shall become, upon such written approval by Purchaser, materials commercially used by Purchaser, its
assignees or its sublicensees in the manufacture and commercial sale of Products. 
 1.8 “Confidential
Information” of a party shall mean all information, including but not limited to product specifications, data, know-how, formulations, product concepts, sample materials, business and technical information, financial data, and deal
terms, whether in written form or disclosed orally, visually and/or in another tangible form, disclosed hereunder by such party to one or more other parties. 
 1.9 “Coordinator(s)” shall have the meaning provided in Article 2. 
 1.10 “Current Material(s)” shall mean Supplier’s [*****], which meet the applicable Materials Specifications set forth at Exhibit C-1 and as is defined in
Exhibit C-1. 
 1.10 “Development Material(s)” shall mean each
polymeric material to be developed by Supplier pursuant to each separate Statement of Work to meet the applicable Materials Specifications, but are not used in the manufacture and commercial sale of Products until such Development Materials become
Commercial Materials as set forth above. 
  

 2 
 DexCom Confidential 

 1.11 “Field” shall mean use in [*****]. 
 1.12 “First Shipment” shall mean the date of the first commercial shipment of Commercial Materials to
Purchaser. 
 1.13 “Forecast” shall have the meaning provided in Section 4.2. 
 1.14 “Governmental Authority” shall mean any country, including any political subdivision thereof, court,
instrumentality, or agency thereof, and any other federal, state, or public authority, domestic or foreign, exercising governmental powers and having jurisdiction, and all statutes, laws, ordinances, regulations, orders, decrees, permits, writs,
process and rules issued thereby which may be applicable to the parties’ performance under this Agreement. 
 1.15
“Latent Defect” shall mean a defect that causes Commercial Materials or Current Materials to fail to conform to the Materials Specifications or to the warranties provided by Supplier hereunder, which defect
is not discoverable upon reasonable physical inspection and testing performed pursuant to Sections 4.4 and 7.3 but is discovered at a later time. 
 1.16 “Materials Price” shall mean the prices for Commercial Materials and Current Materials set forth in Exhibit B hereto as such Exhibit may be amended
from time to time to reflect the addition of new Commercial Materials. 
 1.17 “Materials Specifications”
shall mean the specification of the Current Materials as set forth on Exhibit C-1, and the specifications for the Commercial Materials as set forth at Exhibit C-2, or final specification of an applicable Development Material as may be set
forth in a separate Statement of Work to be attached hereto as part of Exhibit C. 
 1.18
“Patent(s)” shall mean any and all (a) patents, (b) pending patent applications, including, without limitation, all provisional applications, substitutions, continuations, continuation-in-part, divisions,
renewals, and all patents granted thereon, (c) all patent-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including, without limitation, supplementary protection
certificates or the equivalent thereof, (d) inventors certificates, and (e) all United States and foreign counterparts of any of the foregoing. 
 1.19 “Product(s)” shall mean continuous glucose monitoring products which utilize Commercial Materials and the Subject Technology. 
 1.20 “Quality Statement” shall have the meaning provided in Section 5.3. 
 1.21 “Quality Systems” shall mean the regulatory, manufacturing, quality control and quality assurance
procedures, processes, practices, standards, instructions and any other attributes that the parties agree upon or that are otherwise required in connection with

  

 3 
 DexCom Confidential 

 
the manufacture of Commercial Materials (including, without limitation any requirements set forth in the Quality Agreement), as set forth in Exhibit D hereto (as such Exhibit
may be amended by mutual agreement of Purchaser and Supplier from time to time). 
 1.22 “Regulatory
Approval” shall mean any approvals (including supplements, amendments, pre- and post—marketing approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g.,
the European Commission or the Council of the European Union), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the manufacture, distribution, use or sale of Products
containing the Commercial Materials in a regulatory jurisdiction. 
 1.23 “Subject Technology”
shall mean all inventions, compounds, know-how, methods, and, materials necessary to make or use Commercial Materials which were developed as of the Effective Date and which include but are not limited to all inventions which are covered by
any claim of any of the patents identified on Exhibit A (collectively, the “Licensed Patents”). 
 1.24 “Supplier’s Facility” shall mean the manufacturing facility or facilities at which Supplier shall manufacture Development Materials, Commercial Materials, or Current Materials. 
 1.25 “Third Party” shall mean any entity other than Purchaser or Supplier or an Affiliate of either.

 2. COORDINATORS. 
 Within ten (10) days after the date hereof, Purchaser and Supplier shall each appoint an authorized representative and a back-up representative (each, a “Coordinator” and
collectively, the “Coordinators”) for the exchange of all communications, other than legal notices, related to the manufacturing, labeling and packaging of the Commercial Materials. Each such party shall provide notice to the
other party as to the name and title of the individuals so appointed. Each party may replace its coordinators at any time for any reason by providing written notice to the other party in accordance with Section 15.4. 
 3. DEVELOPMENT. 
 3.1 Pursuant to a statement of work (“Statement of Work”), Supplier shall conduct research and development efforts related to polymer technologies for use with Purchaser’s continuous glucose monitoring
product platforms. The minimum specifications for each development project shall be set forth in separate Statements of Work, and attached hereto as part of Exhibit C. Such Statements of Work may be amended or added to by written
agreement of the parties. Supplier shall conduct its research and development tasks under this Agreement in good scientific manner and in compliance in all material respects with all applicable laws. Supplier shall maintain complete, current and
accurate records of all work conducted by it and all data and other information resulting from such work. Such records shall fully and properly reflect all work done and results achieved in the performance of this Agreement in sufficient detail and
in good scientific manner appropriate for patent and

  

 4 
 DexCom Confidential 

 
regulatory purposes. Purchaser shall have the right to review such records maintained by Supplier at reasonable times, upon written request. With respect to Development Materials, and any
Development Materials that become Commercial Materials, Supplier shall grant to Purchaser, including its assignees and sublicensees, a worldwide, perpetual license to such Development Materials, exclusive to Purchaser, its assignees and
sublicensees, in the Field subject to the commercial terms set forth in Exhibit B and any amendment thereto. 
 4. PURCHASE
AND SUPPLY. 
 4.1 Purchase and Supply Agreement. During the term of this Agreement, Purchaser agrees to buy, and
Supplier agrees to use commercially reasonable efforts to sell, such quantities of Current Materials and Commercial Materials as may be set forth on purchase orders placed by Purchaser in accordance with the provisions of Section 4.3. The
transfer price for supply of Current Materials and/or Commercial Materials shall be as provided in Section 6.1 and Exhibit B. Subject to each Statement of Work, Supplier shall license and supply Commercial Materials to Purchaser on an exclusive
basis in the Field; provided however, that exclusivity with respect to the license and supply of Commercial Materials as set forth and defined on Exhibit C-2 ([*****]) shall be limited to a period of [*****] from the earlier of (a) the first
commercial sale of [*****], or (b) [*****], subject to the conditions set forth at Exhibit B. Purchaser shall have the right to purchase and use in its Products similar non-infringing materials from one or more Third Parties during the term of
this Agreement. 
 4.2 Forecasts. Each calendar quarter, Purchaser shall provide Supplier with a written [*****] rolling
forecast, by quarter, of its estimated orders for Current Materials and Commercial Materials (each a “Forecast”). Each Forecast is a non-binding estimate and shall not obligate Purchaser to purchase the volume of Current
Materials and Commercial Materials set forth in it; provided, however, that the volume forecasted for the first [*****] of each Forecast shall represent Purchaser’s firm order for such Current Materials and Commercial Materials. Except
with respect to Sections 4.5 and 4.6, Supplier shall not be obligated to manufacture or supply Purchaser with quantities of Commercial Materials in excess of 125% of the [*****] of the preceding forecast provided to Supplier in a Forecast;
provided, however, that Supplier agrees to use reasonable efforts to fill any order by Purchaser in excess of 125% of such Forecast. 
 4.3 Purchase Orders. Purchaser shall order Current Materials and Commercial Materials by submitting written purchase orders, in such form as the parties shall agree from time to time, to Supplier
specifying the quantities of each Current Material and Commercial Material ordered, the desired shipment date for such Current Material or Commercial Materials, and any special shipping instructions. Purchaser shall submit each purchase order to
Supplier at least [*****] in advance of the desired shipment date specified in such purchase order. Supplier shall make each shipment of Current Material or Commercial Materials in the quantity and before or up to [*****] after the shipment date
specified for it on Purchaser’s purchase order, via the mode(s) of transportation and to the party and destination specified on such purchase order. Shipment shall be F.O.B. the Supplier Facility. Any purchase orders for Current Material or
Commercial Materials submitted by Purchaser to Supplier shall reference this Agreement and shall be governed exclusively by the terms contained herein. The parties hereby agree that the terms and conditions of this Agreement shall supersede any term
or condition in any order, confirmation or other document furnished by Purchaser or Supplier that is in any way inconsistent with these terms and conditions. 
  

 5 
 DexCom Confidential 

 4.4 Materials Specifications; Testing. Current Material and Commercial Materials
supplied hereunder will conform to the Materials Specifications as set forth in Exhibit C-1 and Exhibit C-2, respectively, and Quality Systems (as amended from time to time by written agreement between the parties) and such conformance will be
verified in accordance with the testing standards and procedures specified therein. Supplier will test each batch of Current Material and Commercial Materials and supply Purchaser with a certificate of analysis (“Certificate of
Analysis”) confirming that such meets the Materials Specifications. Purchaser may then retest the batch of Current Material or Commercial Materials as more fully set forth in Section 7.3 to confirm that it meets Materials
Specifications. Accordingly, Purchaser and Supplier agree to negotiate in good faith to modify Materials Specifications from time to time as the parties’ experience with the manufacture, testing and use of Current Material or Commercial
Materials warrants; and Supplier further agrees that it will make reasonable efforts to facilitate changes to Materials Specifications that are necessary or appropriate in light of regulatory requirements. The parties agree to allocate on an
equitable basis any special costs of developing and implementing revised procedures, including capital expenses. 
 4.5
Bridge Inventory. During the final [*****] of this Agreement, or, in the event of any termination of this Agreement for any reason, Purchaser, on behalf of itself or any of its assignees or sublicensees, shall have the option of placing,
in addition to its regular purchases, a final purchase order for bridge inventory of Current Material or Commercial Materials equal to up to [*****] supply of such Current Material or Commercial Materials for delivery after the termination or
expiration of this Agreement at the price in effect as of the effective date of termination. If Purchaser exercises its right under this Section 4.5, then (a) Supplier may deliver such final order after the termination of this Agreement
upon the timeframe requested by Purchaser, or its assignees or sublicensees, to ensure adequate shelf life, and (b) notwithstanding the termination or expiration of this Agreement, the relationship of the parties hereto and all Current Material
or Commercial Materials delivered to Purchaser after such termination or expiration of this Agreement shall be governed by all the terms of this Agreement, including but not limited to Purchaser’s continuing Royalty payment obligations.

 4.6 Failure to Supply. In the event that Supplier is unable or unwilling to manufacture and supply any Current
Material or Commercial Materials in accordance with the terms of this Agreement (a “Failure to Supply”), Purchaser, including its assignees or sublicensees, shall have the right to use (including a right to sublicense) any
necessary intellectual property or know-how applicable to the Current Material and Commercial Materials under the Agreement to enable a third party to manufacture and supply materials to Purchaser or its assignees or sublicensees, which right shall
be subject to payment of applicable unit royalties at the rate existing at the time that a Failure to Supply occurred, subject to reduction for Purchaser’s actual out-of-pocket expenses incurred due to Supplier’s Failure to Supply up to an
aggregate cap on such expenses of $[*****]. In the event of a Failure to Supply, Supplier agrees to support the third party manufacturer’s efforts by providing, without limitation, reasonable technology transfer and assistance to Purchaser or
such third party manufacturer. 
  

 6 
 DexCom Confidential 

 5. MANUFACTURE & LICENSE. 
 5.1 Manufacture of Materials. Supplier shall manufacture Current Material and Commercial Materials in accordance with the Materials
Specifications and all Applicable Laws, as then in effect, including without limitation all laws and regulations of such territories applicable to the transportation, storage, use, handling and disposal of hazardous materials according to local,
state and federal regulations. If new laws, rules or regulations become Applicable Laws, Supplier will make reasonable efforts to comply and the parties shall negotiate in good faith an equitable price adjustment for the Current Material and
Commercial Materials to reflect an appropriate allocation of any increased costs actually borne by Supplier in complying with such Applicable Laws. Without limiting the generality of the foregoing, Supplier shall (a) take all reasonable steps
necessary to ensure that any Current Material or Commercial Materials that may be produced by it pursuant to this Agreement shall be free of cross-contamination from any other manufacturing or similar activities and (b) be responsible for
validated cleaning and changeover procedures prior to manufacturing Current Material or Commercial Materials hereunder. Each party shall promptly notify the other of any new instructions or specifications required by Applicable Laws and shall confer
with each other with respect to the best means to comply with such requirements. Upon request and at mutually agreeable times, Supplier will permit representatives of Purchaser to observe such manufacture and to have access to any relevant records
in connection with such manufacture. Upon Purchaser’s written request, Supplier shall supply Purchaser with copies of Supplier’s manufacturing records for the purposes of assuring Current Material quality and Commercial Materials quality
and compliance with Supplier’s manufacturing procedures. Purchaser acknowledges that all copies of Supplier’s manufacturing records shall be protected under the confidentiality provisions of Article 13. Supplier represents and
warrants to Purchaser that it has and will maintain during the term of this Agreement all government permits, including without limitation health, safety and environmental permits, necessary for the conduct of the actions and procedures that it
undertakes pursuant to this Agreement. 
 5.2 Non-U.S. Legal Requirements. If Purchaser requires Current Material or
Commercial Materials to be manufactured in accordance with any rules and regulations of Governmental Authorities outside the United States, Purchaser shall notify Supplier in writing of such requirements reasonably in advance of the date that such
requirements must be implemented. Supplier shall provide Purchaser with prompt written notice of whether it is able to, and will, comply with such additional requirements. The parties shall discuss a fair apportionment of any material increases in
the cost of manufacture of Current Material or Commercial Materials that result from such additional requirements. Each party shall promptly notify the other of any new instructions or changes to Materials Specifications required by any Governmental
Authority. The parties shall confer with each other with respect to the best means to comply with such requirements. However, Supplier is not required to comply with foreign rules, unless agreed to in writing by both parties. 
 5.3 Quality Statement. Exhibit D attached hereto further details the quality assurance obligations of the parties
with respect to the Current Material and the Commercial Materials (the “Quality Statement”). Notwithstanding anything to the contrary in this Agreement or any other document or agreement, in the event of a conflict between,
this Agreement and the Quality Statement, this Agreement shall govern. 
  

 7 
 DexCom Confidential 

 5.4 Regulatory Support. Purchaser and Supplier shall use commercially reasonable
efforts to respond to all reasonable requests for information from, and in making all required filings with, federal, state or local governmental or regulatory authorities having jurisdiction to make such requests or require such filings. Supplier
shall obtain and comply with all licenses, consents, permits and regulations which may from time to time be required by appropriate governmental and regulatory authorities with respect to the performance of its obligations hereunder. 
 5.5 QA Audits. Upon Purchaser’s reasonable written advance request to Supplier, Purchaser shall have the right to have
representatives visit the Supplier Facility during normal business hours to review Supplier’s manufacturing operations and assess its compliance with quality assurance standards and to discuss any related issues with Supplier’s
manufacturing and management personnel. 
 5.6 Change in Manufacturing Process. Supplier shall obtain Purchaser’s
prior written approval, which shall not be unreasonably withheld, before Supplier implements any change in the Current Material or Commercial Materials, equipment, processes or procedures used to manufacture the Current Material or Commercial
Materials. Supplier shall disclose all such proposed changes in such manufacturing Current Material or Commercial Materials, equipment, processes or procedures to Purchaser at a level sufficient to allow Purchaser to reasonably evaluate the effect
of such changes. 
 5.7 Failed Batch. Supplier shall investigate, and cooperate fully with Purchaser in investigating,
any batch of Current Material or Commercial Materials that fails to meet Materials Specifications or the requirements of any U.S. Governmental Authority with jurisdiction over the manufacture of Materials. Supplier shall keep Purchaser informed of
the status of any investigation and, upon completion of the investigation, shall provide Purchaser with a final written report describing the cause of the failure and summarizing the results of the investigation. 
 5.8 Documentation. Supplier shall keep complete, accurate and authentic accounts, notes, data and records of the work performed under
this Agreement adequate to comply with all Applicable Laws. Supplier shall maintain complete and adequate records pertaining to the methods and facilities used for the manufacture, processing, testing, packing, labeling of the Current Material or
Commercial Materials in accordance with the Applicable Laws. 
 5.9 License Grant. 
 (a) [*****]. Supplier hereby grants to Purchaser, including its assignees or sublicensees, under the Licensed Patents, for the Term
of this Agreement, subject to Sections 4.5 and 4.6, an exclusive, worldwide right and license in and to the Commercial Material set forth on Exhibit C-2 ([*****]) and Subject Technology to make, use, market, sell and offer for sale Products solely
in the Field. 
  

 8 
 DexCom Confidential 

 (b) Development Materials and Commercial Materials [*****]. Supplier hereby grants
to Purchaser, including its assignees or sublicensees, under the Licensed Patents, for perpetuity, and subject to Sections 4.5 and 4.6, an exclusive, worldwide right and license in and to Development Materials and Commercial Materials ([*****]) and
Subject Technology to make, use, market, sell and offer for sale Products solely in the Field. 
 5.10 No Implied
Rights. Supplier shall retain all other rights to the Subject Technology. Except as is expressly provided in this Agreement, neither party shall be deemed to have granted to the other, and there shall not arise by implication or
otherwise, any rights whatsoever by reason of the execution or performance of this Agreement. 
 6. PRICES AND PAYMENT. 

 6.1 Materials Price. For all Current Materials and Commercial Materials supplied to Purchaser pursuant to this
Agreement, Purchaser shall pay to Supplier the Materials Price set forth in Exhibit B hereto. The parties acknowledge and agree that Supplier shall be responsible for all payments to Third Parties for all inputs purchased from, or
other product or services provided by Third Parties in connection with the manufacture and packaging of Current Materials and Commercial Materials. If at any time there is any significant increase in Supplier’s cost of manufacturing Current
Materials or Commercial Materials due to cost changes imposed by any raw material components, fully burdened labor costs and testing services, Supplier shall have the right to increase the price of Current Materials or Commercial Materials
consistent with such increased costs, provided that Supplier provides the supporting documentation to Purchaser to justify the price increase. 
 6.2 Invoices. Supplier shall invoice Purchaser for the aggregate Materials Price of each shipment of Current Materials or Commercial Materials at the time of such shipment. 
 6.3 Payment. Each invoice shall be paid to Supplier in United States Dollars not later than [*****] following the later of
(i) the receipt of the applicable invoice or (ii) the receipt of the relevant batch of Current Materials or Commercial Materials at its destination, unless such shipment of Current Materials or Commercial Materials is properly rejected
under the provisions of Section 7. Any invoiced amount which is not paid within [*****] of its due date shall be assessed a late payment fee at the rate of [*****] per month or the maximum rate permitted by applicable law with respect to such
obligations, whichever is less, unless subject to a valid dispute 
 6.4 Royalty. In addition to the materials
prices referenced in Section 6.1 and Exhibit B for the Current Materials and Commercial Materials, Purchaser shall pay to Supplier the applicable [*****] royalty set forth on Exhibit B for the applicable Commercial Materials
(which shall include Development Materials that become Commercial Materials as set forth in Section 1.7 above). Within [*****] after the end of each Purchaser quarter, Purchaser shall deliver to Supplier a report setting forth [*****] which
contain royalty-bearing Commercial Materials and the amount of unit royalty due hereunder. Payment of the unit royalty shall be remitted within [*****] days after the end of each such quarter. Purchaser shall keep accurate books and accounts of
record in connection with the calculation

  

 9 
 DexCom Confidential 

 
of Product royalty payments to be made under this Agreement. Purchaser shall maintain such records for a period of at least [*****] after the end of the calendar year in which they were
generated. Upon [*****] prior written notice, Supplier may audit, at Supplier’s expense, the relevant books and records of Purchaser as may be reasonably necessary to verify the accuracy of the reports submitted by Purchaser in connection with
the payment of the Product royalty hereunder; provided, that Supplier shall not conduct more than one such audit in any calendar year. 
 7. DELIVERY AND ACCEPTANCE. 
 7.1 Delivery. Unless otherwise agreed by the parties in writing, all
shipments of Current Materials and Commercial Materials shall be shipped F.O.B. the Supplier Facility. Supplier will package and ship Current Materials and Commercial Materials in accordance with the requirements of Purchaser as agreed to by
Supplier. 
 7.2 Timely Delivery. Supplier agrees to use its commercially reasonable efforts to ensure that Current
Materials and Commercial Materials ordered by Purchaser hereunder shall be delivered on the scheduled delivery dates set forth in the relevant purchase orders. 
 7.3 Acceptance and Rejection. 
 (a) Purchaser may reject any batch
delivery which does not conform with the Materials Specifications or to applicable documentation and process requirements. Any such notice of rejection shall be in writing and shall indicate the reasons for such rejection. 
 (b) In order to reject delivery of a full batch of Current Materials or Commercial Materials, Purchaser must give written notice to
Supplier of Purchaser’s rejection of any delivery within [*****] after receipt of such delivery. If no such notice of rejection is timely received, Purchaser shall be deemed to have accepted such delivery of Current Materials or Commercial
Materials within [*****] of delivery of the batch. Once Purchaser accepts a batch of Current Materials or Commercial Materials, Purchaser shall have no recourse against Supplier if the product is subsequently deemed unsuitable for use for any reason
except for Latent Defects. 
 (c) After notice of rejection is given, Purchaser shall cooperate with Supplier in
determining whether rejection is necessary or justified. Supplier will evaluate process issues and other reasons for such non-compliance. Supplier shall notify Purchaser as promptly as reasonably possible whether it accepts Purchaser’s basis
for any rejection. If Supplier in good faith disagrees with Purchaser’s determination that certain Current Materials or Commercial Materials do not meet the Materials Specifications, such Current Materials or Commercial Materials shall be
submitted to a mutually acceptable Third Party laboratory. Such Third Party laboratory shall determine whether such Current Materials or Commercial Materials meets the Materials Specifications and the parties agree that such laboratory’s
determination shall be final and determinative. The party against whom the Third Party tester rules shall bear all costs of the Third Party testing. Whether or not Supplier accepts Purchaser’s basis for rejection, promptly on receipt of a
notice of rejection of a full batch of Current Materials or Commercial

  

 10 
 DexCom Confidential 

 
Materials, Supplier shall use reasonable efforts at Purchaser’s request to replace such rejected Current Materials or Commercial Materials. If the Third Party tester rules that the batch
meets Materials Specifications, Purchaser shall purchase that batch and any replacement batch at the agreed-upon price, irrespective of whether Supplier has already replaced it. 
 (d) Purchaser may not destroy any batch of Current Materials or Commercial Materials until it receives written notification from
Supplier that Supplier does not dispute that the batch fails to meet Materials Specifications and that Supplier does not request return of the Current Materials or Commercial Materials. Upon authorization from Supplier to do so, Purchaser shall
destroy the Current Materials or Commercial Materials received in the rejected delivery promptly at Supplier’s cost and provide Supplier with certification of such destruction. Purchaser shall, upon receipt of Supplier’s request for
return, promptly return said Current Materials or Commercial Materials or quality control sample to Supplier, at Supplier’s cost. 
 8. INTELLECTUAL PROPERTY RIGHTS. 
 8.1 Background Technology. Each party shall retain all right,
title and interest in all technology (including all Patents, copyright, trade-secret and other intellectual property rights therein) that: (i) was created by such party’s personnel or otherwise obtained by such party prior to the date of
this Agreement, and with respect to future development under Section 3, was created by such party’s personnel or otherwise obtained by such party prior to each subsequent Statement of Work, or (ii) is created by such party’s
personnel or otherwise obtained by such party on or after the date of this Agreement and each subsequent Statement of Work, independently and outside the scope of this Agreement and each subsequent Statement of Work (“Background
Technology”). To the extent a party provides any of its Background Technology to the other party pursuant to this Agreement and each subsequent Statement of Work and consents to inclusion of such Background Technology in the development
of the Commercial Materials and Development Materials contemplated by Agreement and each subsequent Statement of Work, then such providing party grants to the other a non-exclusive license, and except for Purchaser’s rights in
Section 15.2, without the right to sublicense, to use such Background Technology, as applicable, solely for the development of the Commercial Materials and Development Materials pursuant to this Agreement, and thereafter with respect to
Background Technology owned by Supplier, for use by Purchaser, or its assignees or sublicensees, in its Products within the Field. 
 8.2 New Technology. To the extent a party creates or develops materials or technology in connection with a mutually executed subsequent Statement of Work (“New Technology”), such party will promptly
notify the other party of such invention. 
 (a) Ownership. As between the parties, ownership of New Technology will be
as follows: 
 (i) Each party will own all right, title and interest in all New Technology (including all Patents, copyright,
trade-secret and other intellectual property rights therein) invented or authored solely by such party’s personnel (including third parties working on such party’s behalf) in connection with performance under this Agreement. 
  

 11 
 DexCom Confidential 

 (ii) With the exception of any Patent with at least one claim reciting the term [*****],
Supplier will own all right, title and interest in all New Technology (including all Patent, copyright, trade-secret and other intellectual property rights therein) that personnel of Supplier and Purchaser (including third parties working on each
party’s behalf) jointly create (“New Technology Intellectual Property of Supplier”), and Purchaser shall have, and Supplier shall grant to Purchaser, including its assignees and sublicensees, a worldwide, perpetual,
exclusive license to the New Technology Intellectual Property of Supplier pursuant to the terms of this Agreement and on commercial terms as set forth in Section II of Exhibit B. 
 Purchaser will own all right, title and interest in any Patent, which includes at least one claim reciting the term [*****], of the New
Technology that personnel of Supplier and Purchaser (including third parties working on each party’s behalf) jointly create (“New Technology Intellectual Property of Purchaser”). Supplier shall have, and Purchaser shall
grant to Supplier, including its assignees and sublicensees, a worldwide, exclusive license to manufacture Commercial Material, for applications not relating to [*****], under any New Technology Intellectual Property of Purchaser. Under this
Agreement, Purchaser does not grant and shall not grant to Supplier, including its assignees and sublicensees, a license to manufacture Commercial Material, for applications relating to [*****] for any party other than Purchaser, or Purchaser’s
assignees and sublicensees, under any New Technology Intellectual Property of Purchaser. 
 (iii) Each party shall cause each of
its Affiliates, personnel, employees, and consultants of such party to comply with this Section 8.2(a), including but not limited to the assignment of the New Technology to the owner, wherein ownership is determined in accordance with Sections
8.2(a)(i)-(ii). 
 (b) Filing and Prosecution of Patent Applications Relating to New Technology of Intellectual Property of
Supplier. It is understood and agreed upon that, with the exception of Supplier’s obligations as set forth in Sections 8.2(b)(i) and 8.2(b)(ii), Supplier retains the right to make all decisions with respect to the preparation, filing,
prosecution and commercial exploitation of any and all of New Technology of Intellectual Property of Supplier at its sole election and discretion subject to the rights granted in this Agreement. 
 (i) Filing. Supplier shall notify Purchaser and give Purchaser a reasonable opportunity to review and comment upon the text of any
patent application, relating to the New Technology, which Supplier intends to file. Supplier shall reasonably consider Purchaser’s comments on such patent application and shall incorporate such comments to the extent Purchaser demonstrates that
such comments materially affect the Field. Supplier shall consult Purchaser on such patent application, and shall supply Purchaser with a copy of such patent application as filed, together with notice of each filing date and serial number.

 (ii) Prosecution. Supplier shall keep Purchaser advised of the status of prosecution of any patent application,
relating to the New Technology, which Supplier files, and shall consult with Purchaser and provide Purchaser with a reasonable opportunity to review and comment on all material, substantive correspondence received from or to be submitted to any
government patent office or authority with respect to any such patent application. Supplier shall provide Purchaser with an opportunity to review and comment on all correspondence

  

 12 
 DexCom Confidential 

 
(notwithstanding materiality or substance) from or to any government patent office or authority with respect to such patent application. Supplier shall reasonably consider Purchaser’s
comments on such correspondence and submissions and shall incorporate such comments to the extent Purchaser demonstrates that such comments materially affect the Field. 
 (c) Release. For so long as Purchaser, its sublicensees or assigns, are not in breach of Sections 6 and 12 of this Agreement, Supplier hereby agrees and covenants that at no time will it, its
successors, or its assigns make any claim or commence or prosecute against Purchaser, its directors, officers, successors, assigns, other suppliers, customers, or other transferees any suit, action, or proceeding of any kind based on assertion of
infringement of any Patent, issued or issuing at any time concerning the New Technology Intellectual Property of Supplier. 
 8.3 Enforcement of Patent Rights. 
 (a) Notice. If either Supplier or Purchaser becomes aware of any
infringement of any of the Licensed Patents or of any patent of the New Technology Intellectual Property of Supplier, it will promptly notify the other party in writing to that effect and the parties will consult with each other. 
 (b) Purchaser’s Rights to Patent Enforcement. While and as long as its license under this agreement remains exclusive, Purchaser
is empowered: 
 (i) To bring suit in its own name, or if required by law, jointly with Supplier, for infringement of any of the
Licensed Patents or any Patent of the New Technology Intellectual Property of Supplier; 
 (ii) In any such suit, to enjoin
infringement and to collect for its own use, damages, profits and awards of whatever nature recoverable for such infringement; and 
 (iii) To settle any claim or suit for infringement of any of the Licensed Patents or any patent of the New Technology Property of Supplier by granting the infringing party a sublicense under the provisions of Sections 3.1, 5.9 and 8.2 of
this Agreement. 
 (c) Expenses. All expenses in any such suit will be borne entirely by Purchaser. 
 8.4 Representations and Warranties. 
 (a) Patents. Except as provided for in Section 8.2(a)(iii), Supplier may, but shall have no obligation to, prosecute applications and maintain Patents covering the Subject Technology or
Commercial Materials developed, or to be developed, under this Agreement. If it elects to do so, Supplier shall be responsible for any of its expenses, including attorney’s fees, that Supplier incurs in order to obtain or maintain the
patent(s). 
  

 13 
 DexCom Confidential 

 (b) Non-Infringement. Supplier represents and warrants that, to the best of
its knowledge, the Current Materials and Commercial Materials, components thereof and their materials and manufacturing processes, as the same may exist as of the Effective Date, do not infringe any third party patents or other intellectual property
rights, and each party shall reasonably cooperate with the other in any investigations undertaken to determine any potential infringement. 
 (c) Right to Grant License. Supplier represents and warrants in respect to the Licensed Patents (i) that it has the sole legal power to extend the rights granted to Purchaser in this
Agreement; (ii) that it is the owner of the entire right, title, and interest in and to the Licensed Patents; (iii) that it has not granted and will not grant any license(s) or covenant(s) not to sue under the Licensed Patents to any Third
Party in the Field that would restrict rights granted to Purchaser under this Agreement; and (iv) that it has not made and will not make any commitments to others inconsistent with or in derogation of such rights. Derogation of such rights
shall include, but are not limited to, any present and future making, using, selling, or offering for sale, in the Field, for or to a Third Party, of any material covered by any claim of the Licensed Patents 
 (d) Validity of Licensed Patents. Supplier represents and warrants to Purchaser that: (i) it is unaware of any prior art which
would render any of the Licensed Patents applicable to the Commercial Material invalid; (ii) it has not received a third party claim of invalidity or unenforceability of any of the Licensed Patents or the Commercial Material as of the Effective
Date; (iii) it is unaware of any third party allegations of misappropriation of third party trade secrets by Supplier; and (iv) that it is unaware of any third party claim of ownership of or invalidity of any of the Licensed Patents or the
Commercial Material as of the Effective Date. To the best of Supplier’s knowledge, the license granted hereunder will not violate any right of any third party. 
 8.5 Third Party Infringement Claims 
 (a) Breach of Warranty. In the
event of a breach of the warranty given by Supplier in Section 8.4(b), Supplier shall take any one or more of the following actions, simultaneously or sequentially: (a) attempt to redesign the allegedly infringing product so as to make it
non-infringing, and (b) if such redesign is impossible or impracticable, attempt to obtain for itself and the benefit of Purchaser, at Supplier’s expense, a license to manufacture and sell the allegedly infringing product, or (c) only
after attempting, in good faith, to take the aforementioned actions and failing, terminate this Agreement, including without limitation, all licenses granted hereunder. 
 (b) Patent Indemnification. Purchaser and Supplier shall promptly notify each other in writing of any legal proceeding, lawsuit, or other judicial action, involving any claim of infringement of any
patent or intellectual property rights, arising out of Purchaser’s application or use of the Current Materials or Commercial Materials. Supplier shall indemnify, defend, and hold harmless Purchaser, its directors, officers, employees,
customers, successors, assigns, or transferees, from all damages and all liabilities (including, but not limited to, all attorneys fees and costs) arising from any claim that Purchaser’s application or use of the Current Materials or Commercial
Materials supplied under this Agreement infringes any patent or intellectual property rights of any Third Party. Any decision made with respect to settlement of such legal proceeding, lawsuit, or other judicial action shall require approval from
both the Supplier and the Purchaser. 
  

 14 
 DexCom Confidential 

 8.6 Reservation of Rights to the Supplier. The license granted in this Agreement is
subject to a reserved non-exclusive license to the Supplier to make, use, sell, or offer for sale for or to the Purchaser any material covered by any claim of the Licensed Patents. No reservation of rights is granted in this Agreement for the
Supplier to make, use, sell, or offer for sale, in the Field, for or to any Third Party, any material covered by any claim of the Licensed Patents. 
 8.7 No Implied License. Except as expressly provided herein, no party hereto shall be deemed by this Agreement to have been granted any license or other rights to patent rights existing as of the
date hereof, or know-how relating to compounds, formulations, products or processes which are owned, licensed or controlled by another party. 
 9. REGULATORY. 
 9.1 Adverse Event Reporting; Current Materials and
Commercial Materials Complaints. Purchaser shall be responsible for all reporting to regulatory authorities Adverse Events to the extent required based on the use of Current Materials or Commercial Materials supplied by Supplier hereunder in
Purchaser’s Products. Purchaser shall advise Supplier promptly after Purchaser becomes aware of any such Adverse Events. If Supplier becomes aware of any Adverse Events associated with the use of such Current Materials or Commercial Materials,
it shall report all information in its possession regarding such event to Purchaser as soon as practicable after becoming aware of such information, and shall cooperate with Purchaser as necessary to report such event under Applicable Laws.
Purchaser shall also notify Supplier as soon as practicable of any complaints of which it becomes aware regarding problems with Current Materials or Commercial Materials other than those associated with Adverse Events, and Purchaser shall meet and
confer with Supplier with respect to its responses to such complaints and whether any remedial actions by Supplier are indicated by the pattern of complaints. 
 9.2 Regulatory Compliance. Supplier shall comply with all regulatory requirements with respect to Current Materials and Commercial Materials imposed by Applicable Law upon Supplier as the
manufacturer of the Current Materials and Commercial Materials. If new regulatory requirements become Applicable Laws, Supplier will make reasonable efforts to comply and the parties shall negotiate in good faith an equitable price adjustment for
the Current Materials or Commercial Materials to reflect an appropriate allocation of any increased costs actually borne by Supplier in complying with such Applicable Laws. Purchaser shall comply with all regulatory requirements with respect to
Current Materials or Commercial Materials that are imposed by Applicable Law upon Purchaser as the holder of Regulatory Approvals. Supplier shall, on a timely basis, provide

  

 15 
 DexCom Confidential 

 
Purchaser with information in Supplier’s possession relevant to its role as the manufacturer of the Current Materials or Commercial Materials that is reasonably necessary for and relevant to
Purchaser’s obligations hereunder in complying with such regulatory requirements as required by Applicable Laws. 
 9.3
Cooperation. Supplier will provide to Purchaser such documentation, data and other information relating to Current Materials and Commercial Materials as Purchaser may require for submission to Governmental Authorities or as required by
Applicable Laws. Supplier shall also provide, upon request by Purchaser, reasonably necessary information concerning its production processes and quality control procedures with respect to Current Materials and Commercial Materials. 
 9.4 Recalls. In the event Purchaser shall be required or requested by any Governmental Authority (or shall voluntarily decide in good
faith) to recall a Product, Purchaser shall coordinate such recall. If a recall arises predominately as a consequence of Supplier’s negligence, willful misconduct or breach of this Agreement, and does not result from Purchaser’s
negligence, willful misconduct or breach of this Agreement, then Supplier shall reimburse Purchaser for (i) the purchase price paid by Purchaser to Supplier for such recalled materials, and (ii) all of Purchaser’s other direct
reasonable costs and expenses actually incurred by Purchaser in connection with the recall including, but not limited to, costs of retrieving Materials already delivered to customers, costs and expenses Purchaser is required to pay for notification,
shipping and handling charges, and all other costs reasonably related to the recall, not exceeding $[*****] in total. If a recall is due to any reason other than one that is attributable either to Supplier’s negligence, willful misconduct or
breach of this Agreement, or out of Supplier’s negligence, willful misconduct or breach of this Agreement, Purchaser shall pay the costs and expenses of the recall. 
 9.5 Regulatory Inspections. Supplier agrees to inform Purchaser within two (2) business days of any regulatory inquiry, communication or inspection, which directly or indirectly relates to the
manufacture of any of the Current Materials or Commercial Materials. In the event Supplier receives a notice of inspection or an inspection visit by any Governmental Authority which involves Current Materials or Commercial Materials or could impact
Supplier’s ability to produce Current Materials or Commercial Materials, Supplier shall notify Purchaser within twenty four (24) hours. Purchaser, at its option, shall have the right to have its representatives present at any such
inspection by a Government Authority, if the inspection pertains to Current Materials or Commercial Materials. In the event there are written observations (or any other written communication) by a Governmental Authority that involve Current
Materials or Commercial Materials or could impact Supplier’s ability to produce Current Materials or Commercial Materials, or any proposed written response by Supplier to any such inspection, Purchaser shall be informed within two business days
and be provided with copies of all documentation within two (2) business days, and shall have a reasonable opportunity to review and comment on the proposed response. If Purchaser elects to provide input to the response, such input shall be
provided by Purchaser as promptly as possible and Supplier shall in good faith incorporate such input into the response. 
  

 16 
 DexCom Confidential 

 9.6 Incidents or Accidents. Supplier shall immediately notify Purchaser in writing of
any incident or accident experienced by such party that such party in its reasonable judgment believes may affect the quality of Current Materials or Commercial Materials that Supplier is obligated to deliver hereunder or its ability to meet
delivery date obligations hereunder. Such incident or accident shall be immediately investigated by Supplier, and Supplier shall provide a written report within five (5) working days of the results of the investigation of such incidence or
accident to Purchaser. 
 10. REPRESENTATIONS AND WARRANTIES. 
 10.1 Mutual Representations and Warranties. Each party hereby represents and warrants to the other party as follows: 
 (a) Existence and Power. Such party (i) is duly organized, validly existing and in good standing under the laws of the state or
other jurisdiction in which it is organized; (ii) has the power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now
being conducted; and (iii) is in compliance with all requirements of Applicable Laws to the extent required by this Agreement, except to the extent that any noncompliance would not have a material adverse affect on such party’s ability to
perform its obligations under the Agreement. 
 (b) Authorization and Enforcement of Obligations. Such party
(i) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 
 (c) No Consents. All necessary consents, approvals and authorizations of all Governmental Authorities and other persons required to
be obtained by such party in connection with this Agreement have been obtained, except for those which cannot be obtained prior to the regulatory approval of the Commercial Materials or Development Materials. 
 (d) No Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(i) do not conflict with or violate any requirement of Applicable Laws or regulations or any material contractual obligation of such party and (ii) do not materially conflict with, or constitute a material default or require any consent
under, any material contractual obligation of such party. Supplier shall in no event enter into any agreement or arrangement with any Third Party that would prevent or in any way interfere with its obligations pursuant to this Agreement. 

10.2 Supplier Representations and Warranties. Supplier represents and warrants to Purchaser as follows: (a) the Current
Materials and Commercial Materials shall be manufactured in compliance with Applicable Laws; (b) shall conform to the Materials Specifications in effect at the time of shipment; (c) shall conform to the Certificates of Analysis
supplied with the shipment of the Current Materials and Commercial Materials; (d) shall be packaged and shipped in accordance with the Materials Specifications in effect at the time of shipment and the terms of this Agreement; (e) to the
best of Supplier’s knowledge, the Subject Technology, Current Materials, Commercial Materials and Development Materials do not infringe any Third Party patents or other intellectual property rights; and (f) shall be free and clear of any
lien or encumbrance. 
  

 17 
 DexCom Confidential 

 10.3 Warranty Disclaimers and Limitations. EXCEPT AS SET FORTH IN SECTIONS 10.1 AND
10.2, SUPPLIER MAKES NO WARRANTIES WITH RESPECT TO PRODUCT SUPPLIED TO PURCHASER, EXPRESS OR IMPLIED, AND SPECIFICALLY, WITHOUT LIMITATION, SUPPLIER DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST
INFRINGEMENT AND ALL OTHER WARRANTIES ARE EXPRESSLY DISCLAIMED. SUPPLIER HAS NO RESPONSIBILITY FOR PURCHASER’S DETERMINATION AS TO HOW AND WHERE TO USE THE COMMERCIAL MATERIAL IN PURCHASER’S PRODUCTS. 
 10.4 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES
INCURRED BY THE OTHER PARTY, OR ANY PUNITIVE OR EXEMPLARY DAMAGES, WHETHER IN CONTRACT OR TORT OR BASED ON A WARRANTY, EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 11. Intentionally Left Blank. 
 12. INDEMNIFICATION. 
 12.1 Supplier Indemnification. Subject to the
limitations in Section 10.3, Supplier, together with its Affiliates, shall indemnify, defend and hold Purchaser, its Affiliates and their respective directors, officers, employees, consultants and sublicensees other than Supplier (each, a
“Purchaser Indemnitee”) harmless from and against any and all costs, losses, claims, liabilities, fines, penalties, damages and expenses, court costs, and reasonable fees and disbursements of counsel, consultants and expert witnesses
(collectively, “Damages”) incurred or suffered by a Purchaser Indemnitee as a result of Third Party claims, actions or proceedings arising from bodily injury or property damage (collectively, “Third Party Claims”) to the extent
such Third Party Claims are a consequence of (i) the breach of any representation or warranty or other provision of this Agreement by Supplier, or (ii) the negligence or willful misconduct of Supplier or its Affiliates, in each case except
to the extent that such Damages result from the willful misconduct or negligent acts or omissions of a Purchaser Indemnitee or breach of this Agreement. Supplier’s aggregate indemnification obligation to Purchaser or its assigns under this
section shall be limited to the lesser of (a) [*****] or (b) the amount of all fees (including Royalties, development fees, and fees paid for the purchase of Commercial Materials) paid by Purchaser to Supplier. 
 12.2 Purchaser Indemnification. Purchaser shall indemnify, defend and hold Supplier, its Affiliates, and their respective directors,
officers, employees and consultants (each, a “Supplier Indemnitee”) harmless from and against any and all Damages incurred by a Supplier Indemnitee as a result of Third Party Claims to the extent such Third Party Claims

  

 18 
 DexCom Confidential 

 
are a consequence of (i) the breach of any representation or warranty or other provision of this Agreement by Purchaser; (ii) the negligence or willful misconduct of Purchaser, its
Affiliates or Third Party sublicensees; or (iii) arising from any defect or deficiency in any Product, in each case except to the extent that such Damages result from any circumstance as to which Supplier has an indemnity obligation under
Section 12.1. 
 12.3 Notice and Assistance. If a party or any of its directors, officers, employees, consultants,
Affiliates or sublicensees has a right to be indemnified under this Article 12 (each, an “Indemnified Party”), (i) the Indemnified Party shall give prompt notice of such Third Party Claim to the party from whom indemnification is
sought hereunder (the “Indemnifying Party”) and (ii) the Indemnifying Party will have the first right to defend any Third Party Claims for which it is required to Indemnify the Indemnified Party, with the cooperation and at the
expense of such Indemnifying Party, provided that it will not settle any such Third Party Claim without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld. If the Indemnifying Party is defending a
Third Party Claim, the Indemnified Party shall have the right to be present in person or through counsel at substantive legal proceedings. In the event that the parties cannot agree as to the application of Sections 12.1 or 12.2 as to any Damages or
Third Party Claim, the parties may conduct separate defenses of such claim. Each party further reserves the right to claim indemnity from the other in accordance with Sections 12.1 or 12.2 upon resolution of the underlying claim. 
 12.4 Insurance. Each party shall, throughout the term of this Agreement, obtain and maintain, at its own cost and expense, from a
reputable insurance company, comprehensive product liability insurance in reasonable and adequate amounts. Purchaser agrees to name Supplier as additional insured on its policy. The amounts of insurance coverage required hereunder shall not be
construed to create a limit on any party’s liability with respect to its indemnification obligations hereunder. Each party shall furnish the other party a certificate of insurance evidencing such insurance upon request and shall provide the
other party with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. Each party’s obligation to maintain such insurance shall continue until five (5) years after
termination of this Agreement. 
 13. CONFIDENTIALITY. 
 13.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of [*****]
after this Agreement expires or terminates, a party receiving Confidential Information of the other party will (i) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary information of
similar kind and value (but at a minimum each party shall use commercially reasonable efforts to maintain Confidential Information in confidence), (ii) not disclose such Confidential Information to any Third Party without prior written consent
of the disclosing party, and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement. A party shall have no such obligation with respect to any portion of such Confidential Information which:

 (a) is publicly disclosed by the disclosing party, either before or after it becomes known to the receiving party;

  

 19 
 DexCom Confidential 

 (b) was known to the receiving party, without obligation to keep it confidential,
prior to when it was received from the disclosing party; 
 (c) is subsequently disclosed to the receiving party by a
Third Party lawfully in possession thereof without obligation to keep it confidential; 
 (d) has been published by a
Third Party; or 
 (e) has been independently developed by the receiving party without the aid, application or use of
Confidential Information. 
 13.2 Permitted Disclosures. Notwithstanding any other provision of this Agreement,
Purchaser may disclose Confidential Information belonging to Supplier to the extent such disclosure is reasonably necessary for regulatory filings, prosecuting or defending litigation, complying with applicable governmental regulations, conducting
pre-clinical or clinical trials by or for Purchaser and marketing and selling Product. If Purchaser is so required to disclose any Confidential Information belonging to Supplier to a Government Authority or to any other Third Party, Purchaser shall
immediately notify Supplier in writing of all details of the required disclosure and permit Supplier to intervene to oppose, limit or condition such disclosure prior to Purchaser making any disclosure and Purchaser shall make any such disclosure
ultimately required in the most restrictive fashion consistent with the requirement as determined by a court or regulatory agency of competent jurisdiction. Except as otherwise agreed to herein, if Supplier is required by law to disclose any
Confidential Information of Purchaser to a Government Authority or to any other Third Party, Supplier shall immediately notify Purchaser in writing of all details of the required disclosure and permit Purchaser to intervene to oppose, limit or
condition such disclosure prior to Supplier making any disclosure, and Supplier shall make any such disclosure ultimately required in the most restrictive fashion consistent with the requirement as determined by a court or regulatory agency of
competent jurisdiction. 
 13.3 Injunctive Relief. The parties expressly acknowledge and agree that any breach or
threatened breach of this Article 12 may cause immediate and irreparable harm to the disclosing party that may not be adequately compensated by damages. Each party therefore agrees that in the event of such breach or threatened breach and in
addition to any remedies available at law, the disclosing party shall have the right to seek equitable and injunctive relief, without bond, in connection with such a breach or threatened breach. 
 14. TERM AND TERMINATION. 
 14.1 Term. 
 The Term of this Agreement shall commence on the Effective Date, and end on the
earliest of the following events: 
 (a) any termination of this Agreement pursuant to its terms, including under section 14.2
of this Agreement, or 
  

 20 
 DexCom Confidential 

 (b) the later of 
 (i) the life of the last to expire of the Licensed Patents, or 
 (ii) as long after the life of the last to expire of the Patents as Licensee shall continue to make the Royalty payments
required under this Agreement in which case the license granted herein shall be a license in and to all of the Subject Technology except the Licensed Patents. For the purposes of clarity, Purchaser’s obligation to pay Royalties shall remain so
long as Commercial Material purchased by Purchaser is in commercial use or application. 
 14.2 Termination for Material
Breach. Subject to Section 14.3, either party may terminate this Agreement upon written notice to the other party if the other party commits any material breach of this Agreement which the breaching party fails to cure within [*****]
following written notice from the non-breaching party specifying such breach. 
 14.3 Surviving Obligations. Termination
of this Agreement shall not (a) affect any other rights of either party which may have accrued up to the date of such termination or (b) preclude either party from pursuing all rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement. The provisions of Sections 4.5, 4.6, 5.4, 5.9 and 6.4 and Articles 8, 9, 10, 12, 13, 14 and 15 shall survive the termination of this Agreement. 
 15. MISCELLANEOUS. 
 15.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to conflicts of laws provisions. 
 15.2 Assignment. This Agreement is assignable in whole or in part by Purchaser. Supplier may assign this Agreement to any of its
Affiliates or to any successor by merger or sale of substantially all of its business or assets to which this Agreement relates. This Agreement shall be binding upon the successors and permitted assigns of the parties and the name of a party
appearing herein will be deemed to include the names of such party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment which is not in accordance with this Section 15.2 shall
be void. 
 15.3 Arbitration. Any controversy arising under or related to this Agreement, and any disputed claim by any
party against another under this Agreement, excluding any dispute relating to patent validity or infringement arising under this Agreement, shall be settled by arbitration in accordance with the then existing Commercial Arbitration Rules of the
American Arbitration Association (the “Rules”). Upon request by a party, arbitration will be by a panel of three arbitrators within thirty (30) days of such arbitration request. One arbitrator will be selected by
Purchaser, one arbitrator will be selected by Supplier, and the third arbitrator will be selected by mutual agreement of the two arbitrators selected by the

  

 21 
 DexCom Confidential 

 
parties. In any such arbitration, the parties shall select a panel with relevant experience in the medical device industry. Judgment upon the award rendered by the panel shall be final and
nonappealable and may be entered in any court having jurisdiction thereof. In order to conduct discovery, and in addition to the discovery provisions provided under the Rules, the parties expressly incorporate into any arbitration occurring under
this Agreement the discovery rules provided for in the Federal Rules of Civil Procedure of the United States of America. Any arbitration shall be held in San Diego, California, unless the parties hereto mutually agree in writing to another place.
Notwithstanding the foregoing, nothing in this provision shall be construed to bar a party from seeking interim equitable relief in order to preserve the status quo or prevent irreparable harm. 
 15.4 Notices. All notices required or permitted to be given under this Agreement shall be in writing and shall be
sent by registered or certified mail or a reputable courier service, addressed to the signatory to whom such notice is required or permitted to be given or transmitted by facsimile to the number indicated below. All notices shall be deemed to have
been given in the case of mailing on the fifth (5th) day following the date of mailing, as postmarked at the point of mailing, or in the case of delivery by courier on the date of delivery, and in the case of facsimile transmission on the first day following the date of transmission.

 All notices to Purchaser shall be addressed as follows: 
 DexCom, Inc. 
 6340
Sequence Drive 
 San Diego, California 92121 
 Telephone: 858-200-0200 
 Facsimile: 858-875-5324 
 Attention: Legal Department 
 All notices to Supplier shall be addressed as follows: 
 DSM PTG, Inc. 

2810 7th Street 
 Berkeley, CA 94710 
 Telephone: (510) 841-8800 
 Facsimile: (510) 841-7800 
 Attention: Robert Ward 
 15.5 Amendment. No amendment, modification or
waiver of any terms or conditions hereof shall be effective unless made in writing and signed by a duly authorized officer of each party. 
 15.6 Disclaimer of Agency. Neither party is, or will be deemed to be, the legal representative or agent of the other party, nor shall either party have the right or authority to assume, create, or
incur any Third Party liability or obligation of any kind, express or implied, against or in the name of or on behalf of the other except as expressly set forth in this Agreement. 
  

 22 
 DexCom Confidential 

 15.7 Non-Waiver. The failure of a party in any one or more instances to insist upon
strict performance of any of the terms and conditions of this Agreement shall not constitute a waiver or relinquishment, to any extent, of the right to assert or rely upon any such terms or conditions on any future occasion. 
 15.8 Severability. If a court of competent jurisdiction or arbitrator declares any provision of this Agreement invalid or
unenforceable, or if any government or other agency having jurisdiction over any party deems any provision to be contrary to any laws, then that provision shall be severed and the remainder of the Agreement shall continue in full force and effect.
To the extent possible, the parties shall revise such invalidated provision in a manner that will render such provision valid without impairing the parties’ original intent. 
 15.9 Entire Agreement. This Agreement (including all exhibits hereto) embodies the entire, final and complete agreement and
understanding between the parties and replaces and supersedes all prior discussions and agreements between them with respect to its subject matter. 
 15.10 Headings. The headings contained in this Agreement are inserted for reference only and shall not be deemed a part of the text hereof. 
 15.11 Counterparts. This Agreement may be executed in multiple counterparts (which may be delivered by facsimile), each of which
shall be an original and all of which shall constitute together the same document. 
  

 23 
 DexCom Confidential 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the
date first set forth above. 
  

									
	DEXCOM, INC.	 		 	DSM PTG, INC.
		 		 		 		 	
	By:	 	 /s/ Steven Pacelli
	 		 	By:	 	 /s/ Robert Ward

	Name:	 	 Steven Pacelli
	 		 	Name:	 	 Robert Ward

	Its:	 	 Chief Administrative Officer
	 		 	President

  

			
	By:	 	 /s/ Robert Evans

	Name:	 	Robert Evans
	Global Vice President Sales & Marketing

  

 24 
 DexCom Confidential 

 EXHIBIT A 
 Patents Covering the Commercial Materials and Licensed under this Agreement 
 [*****]

  

 A 
 DexCom Confidential 

 EXHIBIT B 
 Materials Pricing 
 I. “Current Materials”
Pricing: 
 [*****] 
 II.
Commercial Material Pricing: 
 [*****] 
 The Royalty Schedule for sales of Products containing a Commercial Material [*****] is set forth below. Purchaser shall pay a fee to Supplier for [*****] containing a Commercial Material commercially sold in a calendar year per the schedule
below (“Royalty”). 
 [*****] 
 Annual Royalty payments shall be capped at [*****]. 
 [*****] 
  

 B 
 DexCom Confidential 

 EXHIBIT C-1 
 [*****] 
  

 C-1 
 DexCom Confidential 

 EXHIBIT C-2 
 [*****] 
  

 C-2 
 DexCom Confidential 

 EXHIBIT C-3 
 [Reserved for future development of materials] 
  

 DexCom Confidential 

 EXHIBIT D 
 Reference is made to ISO 9001-2000 
  

 DexCom Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]